Anti-infective Drugs Market

By Type;

Antibiotics, Antivirals, Antifungals, and Others

By Mode Of Purchase;

Prescription-Based Drugs and Over-The-Counter Drugs

By Indication;

HIV Infections, Pneumonia, Hepatitis, Herpes Simplex Virus, Influenza, and Others

By End-Users;

Hospitals, Homecare, Specialty Clinics, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn103124738 Published Date: August, 2025 Updated Date: September, 2025

Anti-Infective Drugs Market Overview

Anti-Infective Drugs Market (USD Million)

Anti-Infective Drugs Market was valued at USD 133,146.94 million in the year 2024. The size of this market is expected to increase to USD 189,863.45 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.2%.


Anti-infective Drugs Market

*Market size in USD million

CAGR 5.2 %


Study Period2025 - 2031
Base Year2024
CAGR (%)5.2 %
Market Size (2024)USD 133,146.94 Million
Market Size (2031)USD 189,863.45 Million
Market ConcentrationMedium
Report Pages387
133,146.94
2024
189,863.45
2031

Major Players

  • Gilead
  • Merck
  • GlaxosmithKline
  • Bristol-Myers Squibb Company
  • Johnson & Johnson

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Anti-infective Drugs Market

Fragmented - Highly competitive market without dominant players


The Anti-Infective Drugs Market is experiencing strong demand as the global burden of infectious diseases continues to rise. These drugs include antibacterials, antivirals, antifungals, and antiparasitic agents, which are crucial in preventing and treating infections. With infectious diseases accounting for nearly 25% of global health concerns, the need for innovative and effective therapies is steadily increasing.

Market Dynamics

The growing prevalence of drug-resistant infections has intensified the demand for advanced anti-infective therapies. Approximately 18% of bacterial infections worldwide show resistance to conventional antibiotics, creating opportunities for next-generation drug development. Pharmaceutical companies are investing heavily in research to address these unmet medical needs.

Innovation and R&D Investments

Continuous advancements in biotechnology and pharmaceuticals have accelerated the development of novel anti-infective drugs. Around 30% of pipeline drugs in infectious disease research focus on combating resistance and improving patient outcomes. The adoption of combination therapies and targeted drug delivery further supports growth in this market.

Healthcare Demand and Accessibility

Rising healthcare expenditure and greater access to medicines have increased the consumption of anti-infective drugs. With more than 40% of patients in low- and middle-income regions relying on government-funded drug programs, accessibility plays a vital role in shaping market trends. Enhanced distribution channels and generic drug availability are also fueling wider adoption.

Future Market Outlook

The anti-infective drugs market is positioned for sustained expansion, driven by growing resistance rates, continuous drug innovation, and increased treatment awareness. With approximately 22% growth contribution from biologics and advanced formulations, the market is expected to remain a critical segment in global healthcare. Strategic collaborations, improved diagnostics, and preventive medicine will continue to support this sector’s growth.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Mode Of Purchas
    3. Market Snapshot, By Indication

    4. Market Snapshot, By End-Users

    5. Market Snapshot, By Region
  4. Anti-Infective Drugs Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing prevalence of infectious diseases
        2. Technological advancements in drug development
        3. Rising healthcare expenditure
        4. Growing awareness about antimicrobial resistance
      2. Restraints
        1. Antimicrobial resistance
        2. Stringent regulatory requirements
        3. High cost of drug development
        4. Competition from generics
      3. Opportuntiy
        1. Development of novel antibiotics and antivirals
        2. Expansion in emerging markets
        3. Strategic partnerships and collaborations
        4. Focus on combination therapies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Anti-Infective Drugs Market, By Type, 2021- 2031 (USD Million)
      1. Antibiotics
      2. Antivirals
      3. Antifungals
      4. Others
    2. Anti-Infective Drugs Market, By Mode Of Purchase, 2021 - 2031 (USD Million)
      1. Prescription-Based Drugs
      2. Over-The-Counter Drugs
    3. Anti-Infective Drugs Market, By Indication, 2021 - 2031 (USD Million)
      1. HIV Infections
      2. Pneumonia
      3. Hepatitis
      4. Herpes Simplex Virus
      5. Influenza
      6. Others
    4. Anti-Infective Drugs Market, By End-Users, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
    5. Anti-Infective Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Gilead
      2. Merck
      3. GlaxosmithKline
      4. Bristol-Myers Squibb Company
      5. Johnson & Johnson
  7. Analyst Views
  8. Future Outlook of the Market